Research Pipeline

To challenge cancer successfully, innovative diagnostics with improved sensitivity and specificity must be developed. To accomplish this goal, XEPTAGEN is pursuing two approaches that work in synergy, thus building up an integrated strategy to diagnose cancer:

• extending validation of biomarkers-IgM immunecomplexes for lung, breast, ovarian and esophagus cancer;
• developing biochips for the simultaneous detection of biomarkers-IgM immunecomplexes associated to several cancer forms